Raptor Pharmaceutical Corp (NASDAQ:RPTP)

CAPS Rating: 2 out of 5

Recs

1
Player Avatar zzlangerhans (99.77) Submitted: 11/15/2012 1:47:13 AM : Outperform Start Price: $4.49 RPTP Score: +181.09

I'm a long-term skeptic on Raptor, but I believe the stock is due for a turn-around before the DR Cysteamine PDUFA for cystinosis on January 30. Will convenience and a reduction in side effects convince insurers to pay 10-20 times as much as they pay now for the current therapy? I doubt it, and I don't think traders buying into the PDUFA will stick around to find out. Far-fetched use of the same compound for Huntington's disease and NASH is still in pie-in-the-sky stage and won't provide much lift until late 2013. This is a quick ditch if I have a positive score going into the PDUFA.

Featured Broker Partners


Advertisement